Predictive Oncology raised $343.5 million through private placements to support a digital asset treasury strategy focused on Aethir's ATH token, aiming to enhance computational capabilities for AI-driven drug discovery.

U.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.

Predictive Oncology will implement a 1-for-15 reverse stock split on September 30, 2025, to maintain Nasdaq listing compliance by addressing minimum bid price requirements.

Predictive Oncology and Every Cure are collaborating to use AI platforms for identifying and repurposing existing drugs for cancer treatments, leveraging their respective AI technologies and extensive biobanks to accelerate drug discovery and improve patient outcomes.

Law firm Kahn Swick & Foti is investigating the proposed merger between Predictive Oncology and Renovaro, questioning whether the transaction adequately values the company.